论文部分内容阅读
The therapeutic activity of"naked" anti-EGFR antibodies is very modest and Erbitux was approved only for use in combination with chemotherapy by FDA.It is highly desirable to generate so called "Immunoconjugates" by arming the tumor-specific mAbs with cytotoxic drugs to enhance their anti-cancer activity.AbMax has developed several anti-EGFR mAb LA22-immunoconjugates by arming tit with several anti-tumor antibiotics, including Mitomycin (MMC).